Validation pour Ingenuity271

vers la météo de la validation par utilisateur

Ingenuity271

precedent - 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 - suivant

Phrase 97 - PMID ?

In mononuclear cells from obese SP exhibiting hyperinsulinemia , oral administration of NODE ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of SP NODE protein 1 week after initial treatment .

Non annotée
Je ne sais pas
Je n'ai pas trouvé d'analyse satisfaisante

Commentaires :

Analyse 0

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 1

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 2

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 3

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 4

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 5

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 6

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 7

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 8

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 9

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 10

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 11

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 12

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 13

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 14

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 15

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +---------SUBJ:V-N---------+                                    |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 16

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 17

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 18

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +---------SUBJ:V-N---------+                                    |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 19

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 20

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 21

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 22

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +---------SUBJ:V-N---------+                                    |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 23

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 24

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +---------SUBJ:V-N---------+                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 25

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 26

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 27

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 28

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +---------SUBJ:V-N---------+                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 29

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 30

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +---------SUBJ:V-N---------+                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 31

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 32

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 33

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 34

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 35

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 36

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 37

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |        |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 38

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |        |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 39

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 40

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |        |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 41

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |        |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 42

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |        |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 43

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 44

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 45

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 46

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 47

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 48

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 49

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 50

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 51

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 52

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 53

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 54

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 55

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 56

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 57

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 58

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 59

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 60

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 61

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 62

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 63

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 64

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 65

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 66

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 67

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 68

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 69

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 70

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 71

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 72

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 73

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 74

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 75

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 76

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 77

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 78

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 79

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 80

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 81

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 82

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 83

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 84

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 85

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 86

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 87

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 88

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 89

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 90

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 91

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 92

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 93

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 94

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 95

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 96

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 97

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 98

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 99

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 100

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 101

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 102

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 103

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 104

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 105

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 106

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 107

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 108

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 109

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 110

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 111

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 112

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 113

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 114

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 115

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 116

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 117

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 118

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 119

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 120

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 121

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 122

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 123

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 124

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 125

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 126

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 127

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 128

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 129

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 130

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 131

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 132

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 133

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 134

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 135

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 136

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 137

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 138

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 139

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 140

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 141

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 142

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 143

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 144

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 145

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 146

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 147

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 148

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 149

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 150

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 151

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 152

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 153

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 154

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 155

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 156

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +---------SUBJ:V-N---------+                                    |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |                                    |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 157

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 158

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 159

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +---------SUBJ:V-N---------+                                    |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |                                    |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 160

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 161

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +---------SUBJ:V-N---------+                                    |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |                                    |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 162

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 163

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 164

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 165

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 166

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 167

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 168

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 169

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +---------SUBJ:V-N---------+                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 170

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 171

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 172

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 173

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +---------SUBJ:V-N---------+                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 174

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 175

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 176

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 177

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 178

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 179

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 180

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 181

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 182

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 183

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 184

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 185

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 186

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 187

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 188

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 189

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 190

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 191

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 192

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 193

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 194

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 195

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 196

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 197

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 198

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 199

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 200

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 201

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 202

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 203

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 204

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 205

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 206

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 207

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 208

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 209

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 210

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 211

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 212

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 213

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 214

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 215

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                   +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 216

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 217

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 218

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                    +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 219

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 220

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 221

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 222

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 223

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 224

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 225

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 226

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 227

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 228

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 229

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 230

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 231

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 232

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 233

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 234

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 235

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 236

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 237

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 238

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 239

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 240

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 241

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 242

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 243

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 244

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 245

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 246

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 247

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 248

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 249

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 250

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 251

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 252

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 253

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 254

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 255

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 256

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 257

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 258

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 259

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 260

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 261

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 262

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 263

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 264

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 265

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 266

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 267

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 268

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 269

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 270

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 271

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 272

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 273

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 274

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 275

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 276

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 277

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 278

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 279

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 280

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 281

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 282

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 283

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 284

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 285

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 286

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 287

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 288

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 289

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 290

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 291

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 292

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 293

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 294

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 295

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 296

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 297

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 298

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 299

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 300

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 301

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 302

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 303

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 304

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 305

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 306

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 307

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 308

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 309

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 310

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 311

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 312

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 313

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 314

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 315

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 316

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 317

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 318

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 319

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 320

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 321

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 322

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 323

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 324

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 325

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 326

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 327

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 328

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 329

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 330

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 331

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 332

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 333

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 334

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 335

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 336

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 337

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 338

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 339

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 340

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 341

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 342

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 343

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 344

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 345

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 346

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 347

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 348

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 349

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 350

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 351

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 352

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                                               |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 353

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 354

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 355

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 356

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 357

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 358

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 359

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 360

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 361

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 362

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 363

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 364

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 365

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 366

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 367

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 368

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 369

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 370

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 371

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 372

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 373

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 374

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                                             +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                                             |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                                             |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+SUBJ:V-N+---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,__SP__)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 375

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +---------SUBJ:V-N---------+                                    |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |                                    |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
SUBJ:V-N (exhibit,cell)
OBJ:V-N (exhibit,hyperinsulinemia)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 376

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 377

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 378

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 379

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 380

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 381

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 382

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 383

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 384

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+                                                                           
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 385

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 386

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 387

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 388

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 389

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 390

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 391

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 392

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 393

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 394

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 395

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 396

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 397

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |        +-----------------------------------------------------------SUBJ:V-N-----------------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |        |                                                            +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |        |             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +---OBJ:V-N---+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
OBJ:V-N (exhibit,hyperinsulinemia)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,exhibit)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 398

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 399

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 400

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 401

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 402

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 403

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 404

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 405

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 406

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 407

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 408

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 409

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 410

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 411

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 412

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 413

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 414

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 415

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                        |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 416

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                        |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 417

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                        |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 418

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                      |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 419

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                      |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 420

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 421

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 422

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 423

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 424

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 425

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 426

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 427

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 428

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 429

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 430

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 431

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 432

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 433

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 434

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 435

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 436

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 437

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 438

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 439

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 440

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 441

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 442

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 443

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 444

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 445

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 446

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 447

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 448

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 449

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 450

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 451

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 452

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 453

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 454

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 455

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 456

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 457

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 458

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 459

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 460

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 461

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 462

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 463

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 464

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 465

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 466

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 467

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 468

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 469

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 470

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 471

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 472

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 473

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 474

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 475

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 476

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 477

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 478

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 479

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 480

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 481

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 482

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 483

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 484

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 485

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 486

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 487

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 488

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 489

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 490

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 491

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 492

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 493

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 494

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 495

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 496

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 497

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 498

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 499

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 500

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 501

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 502

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 503

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 504

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 505

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 506

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |              +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 507

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 508

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 509

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 510

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                        |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 511

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 512

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 513

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 514

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 515

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 516

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 517

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 518

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                        |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 519

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                        |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 520

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                        |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 521

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 522

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 523

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 524

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 525

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 526

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 527

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 528

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 529

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 530

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 531

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 532

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 533

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 534

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 535

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 536

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 537

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 538

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 539

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 540

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 541

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 542

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 543

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 544

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 545

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 546

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 547

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 548

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 549

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 550

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 551

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 552

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                                               +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 553

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 554

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 555

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 556

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 557

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 558

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 559

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 560

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 561

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 562

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 563

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 564

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 565

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 566

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 567

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 568

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 569

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |                                        |                      |                       +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 570

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 571

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 572

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 573

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 574

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 575

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 576

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 577

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 578

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 579

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 580

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 581

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 582

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 583

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 584

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 585

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 586

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 587

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 588

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 589

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 590

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 591

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 592

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 593

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 594

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 595

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 596

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 597

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+                                                                           
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 598

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 599

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 600

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 601

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  +-------------COMP:N-N(from)-------------+                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,hyperinsulinemia)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 602

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 603

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 604

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 605

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 606

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 607

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 608

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 609

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 610

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 611

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 612

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 613

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 614

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 615

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 616

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 617

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 618

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 619

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 620

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +-------------------------------------------------COMP:V-N(from)-------------------------------------------------+                                                                           
                  |                                        |                      +-----------------------------------------SUBJ:V-N----------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |          +--------MOD_ATT:N-ADJ--------+                      |                       +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          |      +-----MOD_ATT:N-ADJ----+                      |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      |        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (hyperinsulinemia,obese)
MOD_ATT:N-ADJ (hyperinsulinemia,__SP__)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,hyperinsulinemia)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 621

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 622

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 623

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  +--COMP:N-N(from)-+                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,__SP__)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 624

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 625

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 626

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 627

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 628

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 629

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 630

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                 +-------------------------------------------------------------COMP:V-N(from)------------------------------------------------------------+                                                                           
                  |                 |                      +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                 |                      |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |                 |                      +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          +MOD_AT+        +-MOD_ATT:N-N-+            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (__SP__,obese)
MOD_ATT:N-N (hyperinsulinemia,exhibit)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 631

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +------COMP:N-N(from)------+             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 632

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +------COMP:N-N(from)------+             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 633

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +------COMP:N-N(from)------+             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 634

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +------COMP:N-N(from)------+             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 635

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +------COMP:N-N(from)------+             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 636

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 637

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 638

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 639

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 640

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 641

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 642

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 643

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 644

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 645

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 646

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 647

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 648

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 649

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 650

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 651

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 652

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 653

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 654

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    +---------------------------COMP:V-N(after)--------------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 655

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 656

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 657

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 658

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 659

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 660

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 661

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 662

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 663

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 664

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 665

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 666

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 667

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 668

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+---------------------------COMP:V-N(after)--------------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:V-N(after) (decrease,treatment)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 669

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  +------COMP:N-N(from)------+             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 670

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  +------COMP:N-N(from)------+             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 671

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  +------COMP:N-N(from)------+             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 672

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  +------COMP:N-N(from)------+             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 673

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  +------COMP:N-N(from)------+             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 674

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 675

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 676

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 677

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 678

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 679

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 680

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 681

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 682

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 683

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 684

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 685

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 686

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 687

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 688

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 689

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                     +------------------------APPOS------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 690

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 691

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 692

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |             |                      +--------------------------------APPOS-------------------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 693

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 694

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 695

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 696

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 697

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 698

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 699

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 700

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 701

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 702

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 703

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 704

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 705

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 706

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 707

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 708

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |                                                                           
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 709

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 710

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 711

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 712

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                                        |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 713

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 714

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 715

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 716

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 717

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +---------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              |                     +-----------COMP:N-N(of)----------+         |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 718

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 719

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 720

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 721

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 722

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 723

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 724

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 725

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 726

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 727

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 728

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 729

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 730

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 731

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 732

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 733

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 734

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+                                                                           
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                                    
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+-------COMP:N-N(after)-------+      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
COMP:N-N(after) (protein,treatment)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 735

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 736

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 737

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                                        +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  +------COMP:N-N(from)------+             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
COMP:N-N(from) (cell,exhibit)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 738

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 739

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 740

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 741

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 742

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-N (treatment,initial)

Analyse 743

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)

Analyse 744

                  +-----------------------------------------------------------------------COMP:V-N(In)----------------------------------------------------------------------+                                                                           
                  |                          +--------------------------------------------------------COMP:V-N(from)--------------------------------------------------------+                                                                           
                  |                          |             +----------------------------------------------------SUBJ:V-N----------------------------------------------------+          +---------------------COMP:N-N(after)---------------------+      
                  |                          |             |                                              +-------------------OBJ:V-N------------------+                    |          +--------COMP:N-N(of)-------+                             |      
                  |          +-MOD_ATT:N-ADJ-+             +---------APPOS--------+                       +-------OBJ:V-N-------+                      +COMP:N-N(o+         |          |           +-MOD_ATT:N-ADJ-+                             |      
         +MOD_ATT:+          |      +MOD_ATT:+             |            +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+         +--OBJ:V-N-+           |       +MOD_ATT+        +MOD:+      +MOD_ATT:+      
         |        |          |      |        |             |            |         |              |        |       |       |     |             |        |      |   |         |          |           |       |       |        |    |      |        |      
 In mononuclear cells from obese __SP__ exhibiting hyperinsulinemia , oral administration of __NODE__ ( with a dosage of 400 mg/day and a treatment period of 4 weeks ) decreases expression of __SP__ __NODE__ protein 1 week after initial treatment .
MOD_ATT:N-ADJ (cell,mononuclear)
MOD_ATT:N-ADJ (exhibit,obese)
MOD_ATT:N-ADJ (exhibit,__SP__)
APPOS (hyperinsulinemia,administration)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,4)
COMP:V-N(In) (decrease,cell)
COMP:V-N(from) (decrease,exhibit)
SUBJ:V-N (decrease,hyperinsulinemia)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,protein)
COMP:N-N(after) (expression,treatment)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
MOD:ADV-N (after,week)
MOD_ATT:N-ADJ (treatment,initial)